survivin与PTEN、PCNA在子宫内膜癌中的表达及其临床意义

Expression of survivin,PTEN and PCNA protein in endometrial carcinoma and its clinical significance

目的观察survivin、PTEN、增殖细胞核抗原（PCNA）在子宫内膜癌（EMC）中的表达及临床意义。方法运用免疫组化S-P法检测survivin、PTEN、PCNA蛋白在48例EMC、19例子宫内膜不典型增生、23例正常子宫内膜组织中表达情况，及其在EMC不同临床分期、组织学分级、肌层浸润程度表达。结果survivin、PCNA和PTEN在正常子宫内膜、子宫内膜不典型增生及EMC中的表达不同，不典型增生组、EMC组与正常子宫内膜组比较，差异有统计学意义（P〈0．05或0．01），不典型增生组与EMC组比较，差异无统计学意义（P〉0．05）。EMC临床Ⅱ期、ⅢⅣ期survivin表达与Ⅰ期有不同，Ⅲ～Ⅳ期PTEN、PCNA表达与Ⅰ期有不同，差异均有统计学意义（P〈0．05）。不同组织学G2、G3 survivin、PTEN、PCNA表达与G1有不同，差异有统计学意义（P〈0．05或0．01）。无肌层浸润或浸润程度≤1／2组PTEN、PCNA表达与浸润程度〉1／2组不同，差异有统计学意义（P〈0．05）。结论检测survivin、PTEN、PCNA三者的表达水平对判断EMC的恶性程度及预测预后具有一定的临床参考价值。

Objective To investigate the expression of survivin, PTEN and PCNA protein in endometrial carcinoma and its clinical significance. Methods Immunohistochemical SP method was performed to detect the expression of survivin, PTEN and PCNA protein in 48 cases of endometrial carcinoma, 19 cases of endometrial atypical hyperplasia and 23 cases of normal endometrium. The expression of survivin, PTEN and PCNA protein was detected in different clinical stage, histological grade, myometrial invasion of endometrial carcinoma. Results The expression of survivin, PCNA and PTEN protein in normal endometriurn, endometrial atypical hyperplasia and endometrial carcinoma were significantly different （endometrial atypical hyperplasia vs normal endometrium with P 〈 0.05, and endometrial carcinoma vs normal endometrium with P 〈 0.01, while endometrial carcinoma vs endometrial atypical hyperplasia with P〉0.05）. In endometrial carcinoma, the expression of survivin in clinical stage Ⅱgroup and Ⅲ -Ⅳ group was different from in the stage Ⅰ group （P〈0.05） ; the expression of PTEN and PCNA in clinical stage Ⅲ -Ⅳ group was different from in stage Ⅰ group（ P〈 0.05）. The expression of survivin, PTEN and PCNA in histological G2, G3 grade groups of endometrial carcinoma was different from in G1 grade group（P 〈 0.05 or 0.01）. Conclusion Detection of the expression of surviving, PTEN and PCNA could supply some clues for the malignant degree of endometrial carcinoma and the prognosis of patients.